logo

Sangamo Biosciences Inc (SGMO)



Trade SGMO now with
  Date
  Headline
4/4/2018 7:32:22 AM Sangamo Announces Publication In Molecular Therapy Of Preclinical Study Data From MPS II In Vivo Genome Editing Program
3/13/2018 6:33:30 AM Wedbush Is Increasing Sangamo Biosciences Inc (SGMO) FY18 Rev. Estimate To 112.8 M From 48.1 M
3/13/2018 6:33:12 AM Wedbush Is Raising Sangamo Biosciences Inc (SGMO) Q4 18 Rev. Estimate To 31.4 M From 11.1 M
3/13/2018 6:32:59 AM Wedbush Is Increasing Sangamo Biosciences Inc (SGMO) Q3 18 Rev. Estimate To 31.1 M From 10.8 M
3/13/2018 6:32:42 AM Wedbush Is Raising Sangamo Biosciences Inc (SGMO) Q2 18 Rev. Estimate To 31.1 M From 3.4 M
3/13/2018 6:32:23 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) Q1 18 Rev. Estimate To 19.2 M From 22.8 M
3/13/2018 6:30:37 AM Wedbush Is Increasing Sangamo Biosciences Inc (SGMO) FY18 Estimate To 0.00 From -0.59
3/13/2018 6:30:17 AM Wedbush Is Increasing Sangamo Biosciences Inc (SGMO) Q4 18 Estimate To 0.03 From -0.16
3/13/2018 6:30:07 AM Wedbush Is Raising Sangamo Biosciences Inc (SGMO) Q3 18 Estimate To 0.03 From -0.16
3/13/2018 6:29:53 AM Wedbush Is Raising Sangamo Biosciences Inc (SGMO) Q2 18 Estimate To 0.03 From -0.25
3/13/2018 6:29:26 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) Q1 18 Estimate To -0.08 From -0.01
2/28/2018 7:38:21 AM Sangamo Announces U.K. CTA Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatment For Hemophilia B
2/22/2018 7:17:47 AM Sangamo Therapeutics Q4 Consolidated Net Loss $13.1 Mln Or $0.15/Shr Vs Loss Of $9.6 Mln Or $0.14/Shr Last Year
2/22/2018 7:03:47 AM Kite And Sangamo Therapeutics Partner To Develop Next-Generation Engineered Cell Therapies For Cancer Treatment
2/12/2018 4:02:33 PM Sangamo Therapeutics Appoints Heather Turner As SVP And General Counsel
2/12/2018 7:40:12 AM Wedbush Is Increasing Sangamo Biosciences Inc (SGMO) FY18 Rev. Estimate To 48.1 M From 28.7 M